Slide 1: Exchange filing cover letter for Q2 FY23 results presentation
November 11, 2022 The National Stock Exchange of India Limited The Bombay Stock Exchange Ltd Exchange Plaza Phiroze Jeejeeboy Towers Bandra Kurla Complex, Dalal Street, Bandra (E), Mumbai - 400 051 Mumbai- 400 001 (SYMBOL: THYROCARE) (SCRIP CODE 539871) Dear Sirs/Madam, Sub: Presentation- Unaudited
Slide 2: Thyrocare Technologies Limited Quarter Results – Q2 FY22-23
Thyrocare Technologies Limited Quarter Results – Q2 FY22-23 0
Slide 3: Agenda
Agenda 1 What’s keeping us busy 2 Performance Summary 3 Looking ahead – priorities for the year 1
Slide 4: Continued efforts on focus areas to drive sustainable growth
Continued efforts on focus areas which we highlighted to drive sustainable growth Geography • Pin Expansion: Added 400+ active pincodes; 3900+ active pincodes in Q2 FY23 (1+ sample billed) Expansion • Lab Expansion: Our lab network continues to remain at 26 labs (19 RPLS, 3 ZPLs, 1 CPL, 3 PCR labs)
Slide 5: Geography Expansion – Pin Expansion & Lab Network
Geography Expansion – Pin Expansion & Lab Network 19000 Total Pincodes in India 5000 Active pincodes goal by Mar-23 exit 3900 Pincodes active in Q2 FY23 3500 Pincodes active in Q1 FY23 Active pincode – Samples billed in the quarter 3
Slide 6: Customer Connect – Lifestyle Packages & Celebrity Promotions
Customer Connect – Lifestyle Packages & Celebrity Promotions Alcohol Smoking Impact Impact Tejashri Pradhan Ganesh Chaturthi - Maharashtra Hairfall Skin Care Screening Checkup Fitness Weight Manali Manisha Dey Essential Management Durga Pooja – West Bengal & Orissa Sedentary Stress Lifestyle Impact
Slide 7: Agenda
Agenda 1 What’s keeping us busy 2 Performance Summary 3 Looking ahead – priorities for the year 5
Slide 8: Quarter Health-check
Quarter Health-check QoQ Pathology YoY Non-Covid Revenue QoQ Non-Covid Revenue Normalized EBITDA +18% +5% +10% YoY Non-Covid samples QoQ Normalized EBITDA % YoY Radiology Revenue +39% +100 bps +30% (6 Mn samples (30% in Q2 FY23) in this Q) YoY Non-Covid YoY Covid Revenue YoY Total Revenue* Normalize
Slide 9: Consistent QoQ non-covid revenue growth for 3 quarters
We have consistently delivered QoQ non-covid revenue growth for 3 quarters Significant growth in Non COVID over last year Strong recovery of Non COVID business QoQ Non COVID Growth Pathology Revenue (INR Cr) 168.7 +5% 125.2 125.2 71.1 123.3 119.2 2.1 110.7 16.1 2.7 2.1 15.3 117.4 100.5 112.2 117.4 9
Slide 10: Normalized EBITDA continues to grow QoQ in line with revenue growth
Normalized EBITDA continues to grow QoQ in line with the revenue growth YoY revenue growth resulting in Normalized Strong growth in QoQ Normalized EBITDA led by EBITDA growth revenue growth and tight control over costs Pathology Normalized EBITDA (INR Cr) QoQ Non COVID Growth +10% 91.08 41.0 37.5 36
Slide 11: Re-oriented Non-COVID business verticals to explain our strategy
We have re-oriented our Non-COVID business verticals to explain our strategy • Network of 950+ branded and 5000+ third party partners – collections centres, local labs, Franchise nursing homes and small hospitals • API, e-pharmacies, online consults, surgeries, at home healthcare & wellness provider
Slide 12: Core business verticals continue to grow – Franchise and Partnerships
Our core business verticals continue to grow – Franchise business and Partnerships main drivers of growth Non COVID Diagnostics Services Revenue (Rs Cr) Non COVID Diagnostics Services Workload (Lakhs) 72 39 68 37 65 62 33 33 60 34 34 28 28 16 15 24 22 12 6 6 7 7 7 6 6 Q2 FY22 Q3 FY22 Q4 FY22 Q1 FY23
Slide 13: Income Statement – Pathology
Income Statement – Pathology Quarter Q Variance (%) Pathology revenue increased INR crore Q2 FY22 Q1 FY23 Q2 FY23 Seq. YOY 5% Q-o-Q. While it decreased Revenue from operations 168.74 119.24 125.23 5% -26% 26% Y-o-Y, primarily on account Cost of materials consumed/ sold (42.41) (38.26) (39.46) 3% -7%
Slide 14: Non COVID P&L has improved QoQ, but COVID P&L continues to decline
Non COVID P&L has improved QoQ, but COVID P&L continues to decline Non COVID COVID Q2’22 Q1’23 Q2’23 Q2’22 Q1’23 Q2’23 Revenue# 97.60 116.52 123.17 71.14 2.69 2.06 Drop in COVID revenue as the pandemic subsided. GM 63.49 79.16 84.23 62.84 1.79 1.54 COVID revenue through Franchise channel with lower
Slide 15: Income Statement – Radiology
Income Statement – Radiology Quarter Q Variance (%) Revenue from imaging INR crore Q2 FY22 Q1 FY23 Q2 FY23 Seq. YOY services accounted for 7% Revenue from operations 7.47 8.55 9.74 14% 30% consolidated revenue Cost of materials consumed/ sold (1.20) (1.24) (1.67) 35% 39% Gross margin 6.27 7.31 8.07
Slide 16: Income Statement – Consolidated
Income Statement – Consolidated Quarter Q Variance (%) Total revenue increased 6% INR crore Q2 FY22 Q1 FY23 Q2 FY23 Seq. YOY QoQ. While it decreased 23% Revenue from operations 176.21 127.79 134.97 6% -23% YoY, primarily on account of Cost of materials consumed/ sold (43.61) (39.50) (41.12) 4% -6% d
Slide 17: Agenda
Agenda 1 What’s keeping us busy 2 Performance Summary 3 Looking ahead – priorities for the year 15
Slide 18: Partner of choice for diagnostics to all healthcare providers
We aim to be the partner of choice for diagnostics to all healthcare providers 61% 33% Franchise Partnerships + B2G -Mom & Pop collection centers -Online diagnostics aggregators -23 Labs -Local labs -Healthcare platforms -Lab within 200Kms of -Nursing homes & hospitals -Employee Wellness platforms e
Slide 19: Continue to execute against strategy shared in May
We continue to execute against our strategy shared in May – will remain focused on the execution against this agenda + 1 Serve Pharmeasy Online customer base of 2.1 M 5 Continue to improve our value proposition to quarterly transacting users our franchisee network, expand aggressively 2 Partner with
Slide 20: Thank You
Thank You Disclaimer This presentation is for information purposes only and it contains general background information about the Company’s activities. The Company assumes no responsibility to publicly amend, modify or revise any forward looking statements on the basis of any subsequent development,